Cargando…
Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing
Leishmania parasites are the causal agent of leishmaniasis, an endemic disease in more than 90 countries worldwide. Over the years, traditional approaches focused on the parasite when developing treatments against leishmaniasis. Despite numerous attempts, there is not yet a universal treatment, and...
Autores principales: | Martinez-Hernandez, J. Eduardo, Hammoud, Zaynab, de Sousa, Alessandra Mara, Kramer, Frank, do Monte-Neto, Rubens L., Maracaja-Coutinho, Vinicius, Martin, Alberto J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528132/ https://www.ncbi.nlm.nih.gov/pubmed/34668739 http://dx.doi.org/10.1128/Spectrum.01018-21 |
Ejemplares similares
-
Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress
por: do Monte, Rubens Lima, et al.
Publicado: (2022) -
Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach
por: Ibarra-Meneses, Ana Victoria, et al.
Publicado: (2022) -
In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis
por: Khanra, Supriya, et al.
Publicado: (2020) -
Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)
por: Firdessa, Rebuma, et al.
Publicado: (2015) -
Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs
por: Rêgo, Felipe D., et al.
Publicado: (2022)